louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT03407898: The Effect of Different Videolaryngoscopes on Intubation Success in Difficult Airway Patients
Official title: The Effect of Different Videolaryngoscopes on Intubation Success in Difficult Airway Patients
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Mallampati Score, Difficult Intubation, Videolaryngoscope
Lead sponsor: Ankara University
Sponsor class: OTHER
First posted: 2018-01-23
Enrollment: 130
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CROSSOVER
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: patients who has mallampati score \>3

Brief summary: Mallampati score \> 3 generally indicate difficult airway and difficult intubation. Most anesthesiologist usually use this score system to predict difficult airway management. Different laryngoscopes may be useful in management of difficult airway. This study designed to compare different videolaryngoscopes in intubation success in patient of Mallampati score\>3.


Eligibility criteria: Inclusion Criteria:

* mallampati score \>3

Exclusion Criteria:

* patient refusal

Primary outcomes:
measure: intubation time
timeFrame: 60 seconds
Secondary outcomes:
Other outcomes:
Locations:
city: Ankara
country: Turkey
facility: Cigdem Yildirimguclu
Study officials:
affiliation: Ankara University
name: CIGDEM YILDIRIMGUCLU
role: STUDY_CHAIR
References:
Clinical trial NCT04381598: Stevia Rebaudiana Bertoni on Levels of GCF Glucose and Bio-markers in Diabetics.
Official title: Efficacy of Stevia Rebaudiana Bertoni on Levels of GCF Glucose and Bio-markers in Diabetic Patients With Periodontitis-A Split Mouth Randomized Controlled Trial.
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
Conditions: Periodontitis
Keywords: Biomarkers
Gingival crevicular fluid
Glucose
Diabetes
Lead sponsor: SVS Institute of Dental Sciences
Sponsor class: OTHER
First posted: 2020-05-11
Enrollment: 19
Sex: ALL
Minimum age (years): 20
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: one group of subjects receives intervention where as other group of subjects receive placebo.
Primary purpose: SUPPORTIVE_CARE

Brief summary: With the increase in the incidence of diabetes and obesity, among other artificial sweeteners the need of natural non-caloric sweetener with acceptable taste and without any adverse effects is demanding.So,the use of stevia presents beneficial effects to general and oral health and its properties could result potentially effective in the treatment of periodontal diseases.

Detailed description: Stevia is considered as a novel molecule, because it is 100% natural and non caloric sweetener, with more sweetness than sucrose, without any adverse effects. It also demonstrates multiple benefits like anti-plaque effect, anti-diabetic effect, anti-periodontophatics properties, anti-hypertensive properties, anti-cariogenic properties etc. There are many studies conducted on stevia in humans, which justifies my study.

Eligibility criteria: Inclusion Criteria:

* Subjects that will be included in the study are in the age group ranging from 20-70 years -with established diabetes and under medication to maintain normal glycemic state i.e;Hb1Ac \< 7％.
* Oral findings including the presence of minimum of 16 natural teeth with minimum of 4 nonadjacent sites showing pocket depths≥ 5 mm.

Exclusion Criteria:

Subjects will be excluded from the study if they are using

* any type of mouth-rinses or if they had underwent any periodontal therapy within the 3-months of the study or
* if they were under antibiotics within the 3-months of the study.

Primary outcomes:
measure: Bio-marker (Ghrelin) levels in Gingival crevicular fluid.
timeFrame: From baseline to 6-months.
Secondary outcomes:
measure: Probing depth
timeFrame: From baseline to 6-months.
Other outcomes:
Locations:
city: Hyderabad
country: India
facility: SVS Institute Of Dental Sciences
state: Telangana
Study officials:
References:
Clinical trial NCT00545298: Safety and Efficacy of Gaseous Nitric Oxide on Venous Stasis Leg Ulcers
Official title: An Investigation of the Topical Application of Gaseous Nitric Oxide on Safety and Efficacy in Venous Stasis Leg Ulcers of the Lower Extremities
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE2
Conditions: Venous Ulcers
Keywords: Nitric Oxide
Venous Leg Ulcers
Lead sponsor: Nitric BioTherapeutics, Inc
Sponsor class: INDUSTRY
First posted: 2007-10-17
Enrollment: 4
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study will test the safety and efficacy of nitric oxide gas in the treatment of venous leg ulcers

Detailed description: Prospective, single center. Controlled study of a moisture retentive wound dressing and sustained compression with 6 weeks of 8 hour daily nitric oxide treatments.

Eligibility criteria: Inclusion Criteria:

* Must have a venous stasis ulcer between the knee and the ankle.
* Ulcer duration must be 60 days or greater

Exclusion Criteria:

* Has an ulcer that is deemed by the Investigator to be caused primarily by a medical condition other than venous insufficiency
* Suffers from diabetes mellitus with HbA1c ≥ 8%
* Suffers from clinically significant arterial disease
* Is pregnant, a nursing mother or a woman of child bearing potential who is not using an adequate form of contraception (or abstinent)

The above is a partial list of the inclusion and exclusion criteria; however, other inclusion and exclusion criteria may apply.

Primary outcomes:
measure: Wound Healing
timeFrame: Week 20
measure: Adverse Events (AEs) and Serious Adverse Events (SAEs)
timeFrame: up to 24 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Richmond
country: United States
facility: Retreat Hospital, Wound Healing Center
state: Virginia
Study officials:
affiliation: HCA Retreat Hospital
name: Joseph V Boykin, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00156598: Metal Ion Serum Concentrations in Patients With Total Hip Replacements
Official title: Cobalt, Chromium and Titanium Serum Concentrations in Patients With Metal-on-Metal vs. Metal on Polyethylene Total Hip Replacements
Study type: OBSERVATIONAL
Overall status: TERMINATED
Conditions: Osteoarthritis
Keywords: metal ion concentration
Lead sponsor: The University of Texas Health Science Center at San Antonio
Sponsor class: OTHER
Collaborators: name: DePuy Orthopaedics
First posted: 2005-09-12
Enrollment: 5
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Local surgeon's patients who have had a hip implant.

Brief summary: Other research studies have shown that the levels of metals in the blood are slightly increased after patients receive a total hip replacement. We want to learn whether these elevated levels are associated with any adverse effects. We hope this study will help us identify which type of patients have elevated levels of metal in their blood.

Detailed description: It is suspected that the concentration of the metals chromium, cobalt and titanium in the blood will be higher in people with an all metal total hip prosthesis than in those with a plastic and metal prosthesis. To find out if this is true, we will test blood samples for the levels of metal in the blood and compare the values from 3 groups of people:

1. people with metal on metal hip replacements
2. loosening of a plastic and metal prosthesis and
3. evidence of osteoarthritis and are awaiting a total hip replacement.

Eligibility criteria: Inclusion Criteria:

Group 1 - unilateral hip replacement with metal on metal prosthesis, well functioning.

Group 2 - loosening of plastic and metal prosthesis Group 3 - osteoarthritis of the hip and awaiting total hip replacement

Exclusion Criteria:

* renal dysfunction
* other types of metal implants or dental prostheses
* rheumatoid arthritis
* hip infection

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: University of Texas Health Science Center Department of Orthopaedics
name: Lorence Trick, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01603498: Effect of Dexamethasone and Methylprednisolone on Pain, Swelling and Trismus After Third Molar Surgery
Official title: Preemptive Effect of Dexamethasone and Methylprednisolone on Pain, Swelling and Trismus After Third Molar Surgery: a Split-mouth Randomized Triple-blind Clinical Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Pain,
Edema,
Trismus
Keywords: pain measurement,
edema,
trismus
Lead sponsor: Federal University of the Valleys of Jequitinhonha and Mucuri
Sponsor class: OTHER
First posted: 2012-05-23
Enrollment: 18
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: The main aim of the present study was to investigate the effect of preemptive dexamethasone and methylprednisolone to prevent pain, swelling and limitation in mouth opening following third molar extraction.

Detailed description: Third molar surgery is often associated with significant post-surgical sequelae. The trauma caused to soft and bony tissue can result in considerable pain, swelling and trismus. Symptoms begin gradually having a peak 2 days after extraction. The use of corticosteroids such as dexamethasone and methylprednisolone can be a valuable tool when performing moderate to moderately severe oral surgical procedures. No clear consensus have emerged yet regarding patient selection, dosage, timing and type of administration of steroid. In this light, this clinical trial aim to compare the effect of preemptive dexamethasone and methylprednisolone to prevent pain, swelling and limitation in mouth opening following third molar extraction.

Eligibility criteria: Inclusion Criteria:

* Patients with indication of asymptomatic bilateral extractions of lower third molars
* Aged 18 years or older;
* Have a good health and no disease;

Exclusion Criteria:

* Patients with history of any medication treatment within 15 days before the beginning of the research, history of allergy to the drugs, substances or materials used in this study, pregnancy or lactation

Primary outcomes:
measure: Postoperative sequelae following thir molar extraction
timeFrame: up to seven days postoperative
Secondary outcomes:
measure: Analgesic consumption; duration of surgery
timeFrame: up to 7 days
Other outcomes:
Locations:
city: Diamantina
country: Brazil
facility: Universidade Federal dos Vales do Jequitinhonha e Mucuri
state: Minas Gerais
Study officials:
affiliation: Federal University of the Valleys of Jequitinhonha and Mucuri
name: Carlos Eduardo Alcântara, MsC
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02354898: A Study of BBI503 in Advanced Solid Tumors, or BBI503/ Sorafenib in Advanced Hepatocellular Carcinoma
Official title: A Phase I Study of BBI503 Monotherapy in Patients With Advanced Solid Tumors, or BBI503 Plus Sorafenib Combination Therapy in Patients With Advanced Hepatocellular Carcinoma
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Advanced Solid Tumors
Hepatocellular Carcinoma
Lead sponsor: Sumitomo Pharma Co., Ltd.
Sponsor class: INDUSTRY
First posted: 2015-02-03
Enrollment: 60
Sex: ALL
Minimum age (years): 20
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This is an open-label, multicenter, phase 1 dose escalation study of BBI503 monotherapy, or BBI503 in combination with Sorafenib. This study population is adult patients with advanced solid tumors in monotherapy, or adult patients with advanced hepatocellular carcinoma in combination therapy.


Eligibility criteria: Inclusion Criteria:

* Provision of written informed consent.
* ≥ 20 years of age
* Measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
* Male or female patients of child-producing potential must agree to use contraception or avoidance of pregnancy measures during the study and for 30 days after the last BBI503 dose
* Females of childbearing potential must have a negative serum pregnancy test
* Adequate organ function
* Life expectancy ≥ 3 months

Exclusion Criteria:

* Any known symptomatic or untreated brain metastases
* Pregnant or breastfeeding
* Crohn's disease, ulcerative colitis extensive gastric and small intestine resection
* Unable or unwilling to swallow BBI503 daily
* Uncontrolled concurrent disease
* Received other investigational drugs within 4 weeks prior to first dose
* Prior treatment with BBI503

Primary outcomes:
measure: Determine of the Maximum Tolerated Dose (MTD) of BBI503 monotherapy and in combination with Sorafenib by assessing dose-limiting toxicities (DLTs)
timeFrame: 36 days
measure: Number of Participants with Adverse Events as a Measure of Safety and Tolerability
timeFrame: Approximately 7 months
measure: Pharmacokinetic profile of BBI503
timeFrame: 37 days
Secondary outcomes:
measure: Assessment of the preliminary anti-tumor activity by performing tumor assessments approximately every 8 weeks
timeFrame: 6 months
measure: Progression Free Survival
timeFrame: Approximately 7 month
measure: Overall Survival
timeFrame: Approximately1 year
Other outcomes:
Locations:
city: Chiba, Etc.
country: Japan
facility: 5 Sites
Study officials:
References:
Clinical trial NCT01192698: Intravenous Interferon During Liver Transplant
Official title: Intravenous Interferon During the Anhepatic Phase of Liver Transplantation and Prevention of Recurrence of Hepatitis C Virus
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Hepatitis C
Cirrhosis
Keywords: cirrhosis
hepatitis C
Lead sponsor: Wake Forest University Health Sciences
Sponsor class: OTHER
Collaborators: name: American College of Gastroenterology
First posted: 2010-09-01
Enrollment: 15
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The main goal of this study is to prevent liver allograft infection with Hepatitis C virus in hepatitis C positive patients undergoing liver transplantation. The hypothesis is that patients who receive ribavirin immediately before transplant and intravenous interferon alfa 2b during the anhepatic phase(while the liver is removed)will have sustained virologic response post liver transplant.

Detailed description: The study is evaluating intravenous interferon given during the anhepatic phase of lvier transplant. Ribavirin was given as well. Serial measurements for HCV RNA were determined 12, 24 72, 96 hrs and 4 weeks after liver transplant.

Eligibility criteria: Inclusion Criteria:

* liver transplant for hepatitis c

Exclusion Criteria:

* allergy to interferon

Primary outcomes:
measure: HCV RNA Result
timeFrame: 4 weeks after liver transplant
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Wake Forest University Health Sciences
name: Mark W Russo, MD, MPH
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00698698: Study on Tear Proteins in Diabetic Retinopathy of Type 2 Diabetics
Official title: Tear Proteins and Diabetic Retinopathy
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Diabetes Mellitus
Keywords: tear proteins
diabetic retinopathy
HPLC
Mass spectroscopy
Lead sponsor: Dow University of Health Sciences
Sponsor class: OTHER
First posted: 2008-06-17
Enrollment: 350
Sex: ALL
Minimum age (years): 30
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: diabetic population

Brief summary: Diabetes mellitus is becoming a global epidemic. There is a need to devise a non invasive method for detection of diabetes and its related complication. Tear proteins are easy to collect causing no harm to a patient and different studies indicate that tear proteins of diabetic patients are significantly different from non diabetic population. This difference in the composition of tear proteins become more pronounced with advancement of diabetic retinopathy.

Detailed description: Diabetes mellitus causes a significant alteration in tear proteins. If we analyze tear proteins by means of electrophoresis, HPLC, and mass spectroscopy.

We can find different type of tear proteins in different grades of diabetic retinopathy these biomarkers can help in mass screening , diagnosis and management of diabetic population.

Eligibility criteria: Inclusion Criteria:

* diabetic patients with type 2 diabetes
* age above 30
* willing to participate

Exclusion Criteria:

* ocular surface disorders.
* collagen vascular diseases
* Limbal hyperemia
* previous ocular surgery
* creatinine level above 1.0
* liver diseases

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Karachi
country: Pakistan
facility: Dow University of Health Sciences
state: Sindh
Study officials:
affiliation: Dow University of Health Sciences Pakistan
name: Dr. Jamshed Ahmed, FCPS
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06254898: Use of Incentives for Stressful Medical Procedures
Official title: Use of Incentives for Children Undergoing Stressful Medical Procedures
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Healthy
Keywords: pediatrics
child life
medical procedures
Lead sponsor: Children's Hospital Colorado
Sponsor class: OTHER
First posted: 2024-02-12
Enrollment: 187
Sex: ALL
Minimum age (years): 5
Maximum age (years): 17
Standard ages: CHILD
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: The goal of this clinical trial is to learn about the use of incentives in pediatric patients requiring medical procedures. The main questions it aims to answer are:

* Are incentives effective at reducing pediatric anxiety for medical procedures?
* What is the best way to use incentives with pediatric populations requiring medical procedures? Participants will be provided support in preparation for their procedure and during the procedure by a child life specialist and might receive an incentive prize after their procedure. Participants distress levels during the procedure will be observed and they will be asked to rate their anxiety on a visual analog scale.

Researchers will compare the anxiety of those who did or did not receive an incentive after their procedure to see if incentives reduced procedural anxiety.

Detailed description: The purpose of this study is to evaluate the impact incentives have on the distress and cooperation of children undergoing stressful medical procedures. The primary aim is to determine if offering an incentive reduces procedural distress for children undergoing stressful medical procedures. Secondly, if an incentive is offered does the process for offering the incentive (conditional or unconditional) to the patient impact the procedural distress of the patient. Patient anxiety and visit satisfaction will be looked at as secondary measures.

Eligibility criteria: Inclusion Criteria:

* Patients and parent of patients aged 6-100 years who are undergoing a medical procedure
* Patients and parent of patients who are prepared and supported by a certified child life specialist.

Exclusion Criteria:

* Cognitive impairment that negates the use of the outcome tools
* Children younger than 6 years old, or older than 17 years old.

Primary outcomes:
measure: modified Yale Preoperative Anxiety Scale (mYPAS)
timeFrame: Immediately after the intervention/procedure/surgery
measure: Visual Scale Self-Report Anxiety
timeFrame: Immediately after the intervention/procedure/surgery
Secondary outcomes:
measure: Visit Satisfaction Survey
timeFrame: Immediately after the intervention/procedure/surgery
Other outcomes:
Locations:
city: Aurora
country: United States
facility: Children's Hospital Colorado Anschutz
state: Colorado
city: Broomfield
country: United States
facility: Children's Hospital Colorado North Campus
state: Colorado
city: Highlands Ranch
country: United States
facility: Children's Hospital Colorado South Campus
state: Colorado
Study officials:
References:
Clinical trial NCT06786598: The Effect of Body Mass Index and Total Cholesterol Levels on Histopathological Grading in Breast Cancer Patients
Official title: The Effect of Body Mass Index and Total Cholesterol Levels on Histopathological Grading in Breast Cancer Patients
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Breast Cancer
Lead sponsor: Tishreen University
Sponsor class: OTHER
First posted: 2025-01-22
Enrollment: 85
Sex: FEMALE
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: OTHER

Brief summary: Breast cancer is a widespread cancer that affects high percentiles of women worldwide.The development and aggressiveness of breast cancer cells can be evaluated depending on the histopathological grading which reflects the degree of differentiation. Several factors related to lifestyle can impact the development of breast cancer. Obesity is an important factor that received the attention in recent years. The using of body mass index(BMI) is still the common method for identifying obesity which is defined when having 30kg/m² or more. Previous epidemiological and clinical studies found that obesity was correlated with advanced breast cancer especially in postmenopausal patients . Also, the changes in cholesterol levels can influence breast cancer risk in the context of obesity. The findings of other studies is still controversial; many studies revealed that elevated total cholesterol levels could increase breast cancer risk while others found to have no effect. Due to the possibility of previous factors' effect on breast cancer progression, we purposed in this study to assess the association of BMI and total cholesterol with histopathological grading according to menopausal status among a group of breast cancer patients in Syria


Eligibility criteria: Inclusion Criteria:

all participants after ensurement that all their clinical and demoghraphical data are completed

Exclusion Criteria:

metabolic syndromes, as well as patients with statin therapy and hormonal replacement treatment.

Primary outcomes:
measure: Evaluating The effect of body mass index and total cholesterol levels on histopathological grading in breast cancer patients
timeFrame: baseline
measure: Assessing the body mass index between patients via dividing weight(in killogram) by height (in meter squared)
timeFrame: baseline
Secondary outcomes:
Other outcomes:
Locations:
city: Lattakia
country: Syrian Arab Republic
facility: Tishreen university
Study officials:
References:
citation: Llaverias G, Danilo C, Mercier I, Daumer K, Capozza F, Williams TM, Sotgia F, Lisanti MP, Frank PG. Role of cholesterol in the development and progression of breast cancer. Am J Pathol. 2011 Jan;178(1):402-12. doi: 10.1016/j.ajpath.2010.11.005. Epub 2010 Dec 23.